清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 5249: Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study

阿帕蒂尼 医学 内科学 临床终点 不利影响 肝细胞癌 胃肠病学 实体瘤疗效评价标准 进行性疾病 肿瘤科 外科 化疗 临床试验
作者
Jun Liu,Guangbing Li,Qiang He,Shijun Sun,Chuanlin Zhao,Chuandong Sun,Bo Zhang,Yi Cui,Yongqiang Ye,Xu–Ting Zhi,Shiping Li,Shiping Li,Guozheng Pan,Changlin Ma,Jinhua Hu,Jun Li,Suling Wang,Yuangang Qiao,Wanhua Ren,Qi Meng
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5249-5249
标识
DOI:10.1158/1538-7445.am2022-5249
摘要

Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Apatinib is a small molecule TKI inhibitor. Its efficacy and safety for unresectable HCC patients have been demonstrated in randomized controlled clinical studies. However, the efficacy and safety of apatinib in real world is lacking. We are aiming to evaluate the efficacy and safety of apatinib in real world.MethodsPatients of older than 18 years with unresectable HCC confirmed by IHC (Immunohistochemistry) or CT and MR Imaging were enrolled in the study. All patients received apatinib monotherapy or combined with other treatments including TACE and chemotherapy. The enrolled patients were treated until disease progression, death, or severe intolerable toxicity, etc. The primary endpoint was overall response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). The adverse events (AEs) were also recorded.ResultsFrom February, 2019 to May, 2020, a total of 233 patients were enrolled. Among them, 66 (28.33%) patients received apatinib monotherapy and 167 (71.67%) patients received combination therapy. Patients with a history of hepatitis accounted for 70%. 8 patients achieved complete response (CR), 64 patients achieved partial response (PR), 120 patients achieved stable disease (SD), and 41 patients had progressive disease (PD), illustrating an ORR of 30.90% and a DCR of 82.40%. Median PFS and OS were 6.93 months (95% CI, 6.19-7.68 months) and 11.36 months (95% CI, 9.96-12.77 months), respectively. The safety profile indicated that the most common drug-related adverse events were hypertension (37.90%), hand-foot-skin reaction (27.39%), fatigue (19.11%), thrombocytopenia (16.02%). Grade 3/4 treatment related AEs included thrombocytopenia (4.30%), hypertension (3.82%), neutropenia (2.73%). After symptomatic treatment, all the adverse events were treated properly, and no unexpected adverse events were observed. Conclusions In current study, apatininb showed good tolerance with acceptable toxicity and high tumor response rate that translated into promising PFS and OS in unresectable HCC patients. ChiCTR1900021822 Citation Format: Jun Liu, Guangbing Li, Qiang He, Shijun Sun, Chuanlin Zhao, Chuandong Sun, Bo Zhang, Yi Cui, Yongqiang Ye, Xuting Zhi, Shiping Li, Shiping Li, Guozheng Pan, Changlin Ma, Jinhua Hu, Jun Li, Suling Wang, Yuangang Qiao, Wanhua Ren, Qi Meng. Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5249.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朴实惜寒完成签到,获得积分10
5秒前
11完成签到 ,获得积分10
5秒前
7秒前
king完成签到 ,获得积分10
12秒前
wsj完成签到 ,获得积分10
13秒前
Tardes发布了新的文献求助10
14秒前
ss完成签到,获得积分10
17秒前
甜美的梦芝完成签到,获得积分10
19秒前
西瓜柠檬可乐完成签到 ,获得积分10
34秒前
李煜琛完成签到 ,获得积分10
42秒前
悦耳的竺完成签到 ,获得积分10
42秒前
搜集达人的应助被冲冲冲采纳,获得10
43秒前
大力的安阳完成签到 ,获得积分10
46秒前
无花果的应助被ZLPY采纳,获得30
46秒前
53秒前
53秒前
刘亚梅完成签到 ,获得积分10
56秒前
醉熏的小凡完成签到,获得积分10
58秒前
冲冲冲发布了新的文献求助10
59秒前
apt完成签到 ,获得积分10
1分钟前
1分钟前
忧伤的白秋完成签到,获得积分10
1分钟前
1分钟前
lx完成签到 ,获得积分10
1分钟前
天天快乐的应助被hilufite采纳,获得10
1分钟前
nhzz2023完成签到 ,获得积分10
1分钟前
和谐如彤完成签到,获得积分10
1分钟前
nanjing01完成签到 ,获得积分10
1分钟前
如泣草芥完成签到,获得积分10
1分钟前
Jessie完成签到,获得积分10
1分钟前
RZH发布了新的文献求助50
1分钟前
hy发布了新的文献求助10
1分钟前
笙歌完成签到 ,获得积分10
1分钟前
点点完成签到 ,获得积分10
1分钟前
细胞呵呵完成签到 ,获得积分10
1分钟前
cc发布了新的文献求助10
2分钟前
2分钟前
长孙烙完成签到 ,获得积分10
2分钟前
菜鸟学习完成签到 ,获得积分10
2分钟前
wayne完成签到 ,获得积分0
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697